mRNA Cancer Vaccine Met Endpoints in Adjuvant Melanoma

For oncology nurses on the frontlines of cancer care, the era of personalized medicine has reached a historic milestone. Merck and Moderna have announced positive topline results from the Phase 3 INTerpath-001 (NCT05933577) trial, representing the first-ever positive Phase 3 readout for an mRNA-based individualized neoantigen therapy (INT).

This landmark global study met its primary endpoint of recurrence-free survival (RFS) and a key secondary endpoint of distant metastasis-free survival (DMFS) in patients with completely resected stage IIB-IV cutaneous melanoma.

In this double-blind trial, which randomized 1,137 patients 2:1, adjuvant treatment with the custom-manufactured therapy intismeran autogene (V940) combined with pembrolizumab (Keytruda) demonstrated statistically significant and clinically meaningful improvements in both RFS and DMFS compared to pembrolizumab monotherapy. The combination's safety profile remained highly consistent with earlier clinical findings, displaying no new safety signals.

This success builds on the five-year Phase 2b KEYNOTE-942 (NCT03897881) update, which demonstrated a durable 49% reduction in the risk of recurrence or death.

This is the first Phase 3 trial to show a clinical benefit over standard-of-care pembrolizumab alone in the adjuvant melanoma setting. Transitioning these patient-specific mRNA vaccines from clinical trials into standard clinic workflows introduces unique handling challenges. Because intismeran is custom-tailored to the mutational "fingerprint" of each individual patient's tumor, vials are patient-specific and cannot be shared or exchanged. This necessitates extraordinary precision in supply chains, delivery scheduling, and strict cold-chain storage at minus 20 or minus 70 degrees Celsius. Oncology nurses will be central to managing these complex, individualized regimens.

In a recent interview, Melanoma Institute Australia Associate Professor Matteo Carlino, BMedSc, MBBS, FRACP, a prominent clinical investigator and second author on the recent study, discussed the transformative INTerpath-001 findings, the immunological science behind mRNA neoantigen therapies, and the practical logistical and handling preparations required of nursing teams as the developers begin engaging with global regulatory authorities for filing submissions.

What special handling, reconstitution, or administration schedules are required for V940 compared with standard pembrolizumab infusions?

In some ways, it's quite different. I think the first thing that's going to be something that we'll all have to deal with clinically is this product is individualized. So, with pembrolizumab, if we had a patient due for treatment today, and for some reason they couldn't have treatment, that vial of pembrolizumab could be used on the next patient, because of course that that treatment is flat dosed, and every patient gets the same treatment.

V940, or intismeran, is completely different. You cannot use the drug made up for patient X on the next patient. So that's the first thing. That will lead to issues about supply, delivery, and schedules like that.

The second thing that will need to be sorted out when the when the drug moves from the research phase into the standard practice phase is storage. Initially, during the trials, we used to store the product at minus 70 degrees, which of course may not be available at all sites. However, there's been a lot of work about confirming the product stability at minus 20.

But I think for nurses and pharmacists, the main change is the individualized nature of the product, which I'm sure we'll all come to terms with. But that is a difference from just about every other drug we've used in clinical practice.

Does adding an individualized mRNA therapy to pembrolizumab alter the expected adverse effect profile or increase the risk of immune-mediated adverse effects?

No. So that's really, I think, one of the best features of this agent. We saw no increase in the race of rate of immune-related adverse events. In fact, when you looked at the randomized phase 2 study, the rate was numerically slightly lower in the combination arm. So, I think that's a really positive thing, particularly because these patients are being treated in the adjuvant setting, and so permanent immune-related toxicities like cortisol deficiency and the rare side effect of type 1 diabetes, it's really a relief not to see an increase in those type of toxicities.

References

1. Khattak A, Carlino MS, Meniawy T, et al. Intismeran autogene plus pembrolizumab versus pembrolizumab alone in high-risk resected melanoma: 5-year update of the randomized phase IIb KEYNOTE-942 study. J Clin Oncol. Published online 2026. doi:10.1200/JCO-26-00835
2. Merck & Co. Merck and Moderna announce Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA® met endpoints of recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in patients with completely resected stage IIB-IV melanoma. Merck.com. August 19, 2026. Accessed August 25, 2026. https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/